公开(公告)号：US20230321103A1

公开(公告)日：2023-10-12

申请号：US18043419

申请日：2021-09-01

Applicant: East China University of Science and Technology

Inventor： Honglin LI ,  Zhenjiang ZHAO ,  Yanyan DIAO ,  Zhuo CHEN

IPC: A61K31/519

CPC classification number: A61K31/519

Abstract: Provided is the use of a series of pteridinones and/or a pharmaceutically acceptable salt and a prodrug thereof as a non-canonical EGFR mutant inhibitor. Specifically, the present invention relates to the use of a series of compounds as represented by formula I and a pharmaceutical composition containing the series of compounds as represented by formula I in the preparation of a drug for treating a disease containing EGFR 20insX mutation, EGFR G719X mutation and ERBB2 mutation.

公开(公告)号：US20180148454A1

公开(公告)日：2018-05-31

申请号：US15577518

申请日：2016-05-30

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin LI ,  Yufang XU ,  Zhenjiang ZHAO ,  Wei ZHOU ,  Yuqiong XU ,  Deheng SUN ,  Xia WANG ,  Zhuo CHEN

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  C07D475/00

Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.